Navigation Links
Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency
Date:10/6/2010

ISTANBUL, Oct. 7 /PRNewswire/ -- Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. The study found that IgG replacement therapy initiated with Vivaglobin in patients with PI provided adequate serum IgG levels, protected the patients from infections, and improved health-related quality of life, without raising safety concerns.

SCIg treatment, which is delivered directly under the skin, is an important treatment option for patients who do not easily tolerate administration by intravenous infusion because they have poor venous access or experience serious side effects. SCIg is self-administered, offering users convenience and reducing some of the need for healthcare resources associated with IVIg therapy. Additionally, because SCIg is infused weekly, it provides sustained serum IgG levels.

"Though SCIg treatment sustains IgG levels better than IVIg does, for the newly diagnosed patient, IVIg therapy has usually been the recommended first course of treatment," said Bruce Ritchie, MD, FRCPC, Associate Professor, Division of Hematology, Department of Medicine, University of Alberta, and study investigator. "Our findings challenge the practice of initiating replacement therapy using IVIg in people newly diagnosed with primary immunodeficiency disease. The findings also confirm the therapeutic benefits of administering SCIg as first-line treatment in this patient population."

Vivaglobin is approved in the European Union and Switzerland for treating PI as well as secondary immunodeficiency (SI) patients. In Canada and the United States, Vivaglobin is approved for treating PI.

Study DesignIn this study, 18 treat
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
2. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
3. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
4. Botanic Oil Innovations Funds Human Clinical Study Using Non-Toxic Salmonella as Cancer Medicine
5. New Study Shows Telemedicine Works to Effectively Identify Heart Problems in Children Far from a Specialized Medical Center
6. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
7. New National Program to Study and Establish Pediatric Dosing
8. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
9. New Multi-Center Study Finds Clinical Practice Change with Masimo SET Pulse Oximetry Reduces Severe Eye Damage More Than 50% in Premature Newborns
10. New Study Reveals Collagenase SANTYL® Ointment More Effective Than Hydrogel Dressing for Pressure Ulcer Debridement
11. Largest Study of Melanoma in US Hispanics Reveals California Population in Need of Targeted Prevention Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... release its financial results for the fiscal 2014 fourth ... trading ends on Tuesday, September 9, 2014. ... p.m. U.S. EDT on Tuesday, September 9, 2014 (Wednesday, ... Company,s financial results, commercial partnerships, and future outlook.  The ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014  Abaxis, Inc. ... manufacturing point-of-care blood instrumentation and consumables to the medical, ... Severson , Chairman and Chief Executive Officer, will present ... Ideas Conference 2014 on Tuesday, September 9, 2014 at ... the Omni Berkshire Place Hotel in New ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... Colo., Oct. 7 Waleed Danho, Ph.D., Distinguished Research ... 2009 recipient of the Meienhofer Award for excellence in ... RCCPS ( http://www.rochecolorado.com/PeptideSymp09/ ). Hosted ... Boulder, RCCPS is the only global conference exclusively dedicated ...
... Biomedical Corporation, a leading developer of whole blood analyzers, ... Sanvita CBGM, LLC, has completed the acquisition of certain ... Inc. , Nova Biomedical is the sole ... Monitoring (CBGM) subsidiary has become the exclusive distributor, of ...
Cached Medicine Technology:Roche Scientist Recognized for Excellence in Peptide Chemistry 2Roche Scientist Recognized for Excellence in Peptide Chemistry 3Roche Scientist Recognized for Excellence in Peptide Chemistry 4Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:8/30/2014)... August 30, 2014 Daily Gossip reveals in ... Make Him Desire You program, who shows a unique formula ... author of this method says that the program goes beyond ... Make Him Desire You review indicates that the program was ... advice and his great techniques to make a man feel ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... Ticket Down is a ... tickets in NYC. This popular ticket exchange ... all day session, evening session, courtside seats, grandstand seats, ... prestigious Grand Slam Tournament. , The 2014 U.S. Open ... Open Tennis Championship: Men's/Women's 3rd Round - Session 11 ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3
... of the recent recall of eggs by den Dulk ... Nelken is strongly advising Americans, especially pregnant women, children ... eating eggs at home or in restaurants. More than ... the most dangerous foods in terms of food-borne illness. ...
... Blue Shield of California announced two additions to its ... Janet Widmann to senior vice president. The promotions ... and CEO Bruce Bodaken earlier this year, when Paul ... previously vice president of customer service & claims, was ...
... Nicholas Blanco of San Diego, CA, will travel ... 31, 2009 to meet with congressional leaders and gain ... research toward a cure for epilepsy.Blanco, 7, is one ... in Kids Speak Up! , a national program ...
... Women experiencing physical abuse from intimate partners spent 42 ... according to a long-term study of more than 3,000 women. ... The study revealed that women who suffered physical abuse five ... year on health care than women who were never abused. ...
... WASHINGTON, March 23 Alexandria Gray of Chicago, IL, ... Tuesday, March 31, 2009 to meet with congressional leaders ... and more research toward a cure for epilepsy.Gray, 9, ... country participating in Kids Speak Up! , a ...
... the European UnionEAST PROVIDENCE, R.I., March 23 ... the innovative IlluminOss(TM) Photodynamic Bone Stabilization System for ... granted a CE Mark. The approval permits ... European Union (EU).IlluminOss Medical is beginning the process ...
Cached Medicine News:Health News:Food Safety Expert Offers Tips to Be Safe in Wake of Costco & Safeway Egg Recall 2Health News:Blue Shield of California Names Two New Senior Vice Presidents 2Health News:California Youth Shares Epilepsy Message on Capitol Hill 2Health News:Physical abuse raises women's health costs over 40 percent 2Health News:Illinois Youth Shares Epilepsy Message on Capitol Hill 2Health News:IlluminOss(TM) Photodynamic Bone Stabilization System Receives CE Mark 2
... ,The LMA ProSeal™ is the most ... enables seal pressures of 30cm H2O and ... separates the alimentary and respiratory tracts. These ... enable longer periods of ventilation with minimal ...
... superior, disposable supraglottic airway tool that utilizes ... design to provide the best non-intubating airway ... a safe, reliable, cost effective and efficient ... laryngoscopy is not feasible or attainable. With ...
... material, Available in even sizes 20-36F. Single ... maximizing patient comfort. The Latex-Free Robertazzi is ... while offering the best solution for latex ... to offer a quality latex-free product as ...
Soft red rubber. Adjustable flange. Pediatric sizes available....
Medicine Products: